Matter Bio, a NYC-based longevity holding company focused on preserving genome integrity, received an investment from LifeSpan Vision Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space.
co-founded with world-class scientists, including George Church PhD. and Jan Vijg PhD., and led by Chris Bradley, CEO, Matter Bio is a holding company that is advancing multiple scientific results each targeting a critical juncture of information loss. Its core assets include accurate mutation sequencing, reversing somatic mutations, and clearing pathological cells, including cancer.
To date, Matter Bio has three companies under its management, with other opportunities in incubation.
FinSMEs
23/10/2023